Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
announced, arm, Attendance, Brii, challenging, charged, cocktail, Delta, discontinued, Eli, endemic, forthcoming, GlaxoSmithKline, highlighted, improvement, inhibitor, intravenously, Lilly, lot, monoclonal, NIH, peer, persistent, Pfizer, platform, preprint, prevalent, proliferation, protease, Pursing, RBL, repaid, stable, steroid, strong, submission, suitability, TNF, undergone, unmet, variant, wave
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view